352 related articles for article (PubMed ID: 34158154)
1. Epidemiology and Treatment of Chronic Graft-versus-Host Disease Post-Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis.
Bachier CR; Aggarwal SK; Hennegan K; Milgroom A; Francis K; Dehipawala S; Rotta M
Transplant Cell Ther; 2021 Jun; 27(6):504.e1-504.e6. PubMed ID: 34158154
[TBL] [Abstract][Full Text] [Related]
2. Healthcare resource utilization and costs among patients with steroid-resistant chronic graft-versus-host disease in the United States: a retrospective claims database analysis.
Yu J; Lal LS; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
Curr Med Res Opin; 2021 May; 37(5):755-759. PubMed ID: 33615925
[TBL] [Abstract][Full Text] [Related]
3. Healthcare resource utilization and costs associated with acute graft-versus-host disease following allogeneic hematopoietic cell transplantation.
Yu J; Lal L; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
Support Care Cancer; 2020 Nov; 28(11):5491-5499. PubMed ID: 32172407
[TBL] [Abstract][Full Text] [Related]
4. Healthcare Resource Utilization and Costs of Steroid-Associated Complications in Patients With Graft-Versus-Host Disease.
Bell EJ; Yu J; Bhatt V; Bunner SH; Lal LS; Galvin J; Weisdorf D
Transplant Cell Ther; 2022 Oct; 28(10):707.e1-707.e7. PubMed ID: 35483620
[TBL] [Abstract][Full Text] [Related]
5. Treatment Pathways and Health Outcomes of German Patients with Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation: A Retrospective Health Claims Data Analysis.
Scheid C; Kudernatsch R; Eckart M; Feig C; Straub V; Libutzki B; Mahlich J
Drugs Real World Outcomes; 2022 Dec; 9(4):577-588. PubMed ID: 35779205
[TBL] [Abstract][Full Text] [Related]
6. Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy.
Lee CJ; Wang T; Chen K; Arora M; Brazauskas R; Spellman SR; Kitko C; MacMillan ML; Pidala JA; Auletta JJ; Badawy SM; Bhatt N; Bhatt VR; Cahn JY; DeFilipp Z; Diaz MA; Farhadfar N; Gadalla S; Gale RP; Hashem H; Hashmi S; Hematti P; Hong S; Hossain NM; Inamoto Y; Lekakis LJ; Modi D; Patel S; Sharma A; Solomon S; Couriel DR
Transplant Cell Ther; 2022 Oct; 28(10):712.e1-712.e8. PubMed ID: 35863740
[TBL] [Abstract][Full Text] [Related]
7. Inpatient Healthcare Resource Utilization, Costs, and Mortality in Adult Patients with Acute Graft-versus-Host Disease, Including Steroid-Refractory or High-Risk Disease, following Allogeneic Hematopoietic Cell Transplantation.
Yu J; Judy JT; Parasuraman S; Sinha M; Weisdorf D
Biol Blood Marrow Transplant; 2020 Mar; 26(3):600-605. PubMed ID: 31678539
[TBL] [Abstract][Full Text] [Related]
8. Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy.
Lee CJ; Wang T; Chen K; Arora M; Brazauskas R; Spellman SR; Kitko C; MacMillan ML; Pidala JA; Badawy SM; Bhatt N; Bhatt VR; DeFilipp Z; Diaz MA; Farhadfar N; Gadalla S; Hashmi S; Hematti P; Hossain NM; Inamoto Y; Lekakis LJ; Sharma A; Solomon S; Lee SJ; Couriel DR
Transplant Cell Ther; 2024 Jan; 30(1):97.e1-97.e14. PubMed ID: 37844687
[TBL] [Abstract][Full Text] [Related]
9. Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease.
Schain F; Batyrbekova N; Liwing J; Baculea S; Webb T; Remberger M; Mattsson J
Eur J Health Econ; 2021 Feb; 22(1):169-180. PubMed ID: 33275188
[TBL] [Abstract][Full Text] [Related]
10. Treatment-Sensitive and Treatment-Dependent Chronic Graft-versus-Host Disease Yield Superior Failure-Free and Overall Survival Compared to Treatment-Resistant Chronic Graft-versus-Host Disease.
El Jurdi N; Herzog S; Shanley R; Holtan SG; MacMillan ML; Weisdorf DJ
Transplant Cell Ther; 2024 Jun; 30(6):616-625. PubMed ID: 38479549
[TBL] [Abstract][Full Text] [Related]
11. Clinical and economic burden associated with graft-versus-host disease following allogeneic hematopoietic cell transplantation in France.
Michonneau D; Quignot N; Jiang H; Reichenbach D; Kelly M; Burrell A; Zhang X; Thiruvillakkat K; Mohty M
Bone Marrow Transplant; 2023 May; 58(5):514-525. PubMed ID: 36765178
[TBL] [Abstract][Full Text] [Related]
12. Healthcare utilization and cost of cancer-related care prior to allogeneic hematopoietic cell transplantation for hematologic malignancies in the US: a retrospective real-world analysis.
Bonafede M; Anaissie E; Evans K; Itzler R
BMC Health Serv Res; 2021 Oct; 21(1):1125. PubMed ID: 34666775
[TBL] [Abstract][Full Text] [Related]
13. Navigating the Complexity of Chronic Graft-vs-Host Disease: Canadian Insights into Real-World Treatment Sequencing.
Kim D; Taparia M; Robinson E; Mcgee M; Merali T
Transplant Proc; 2024 Mar; 56(2):409-415. PubMed ID: 38342748
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation.
Cheng WY; Avery RK; Thompson-Leduc P; Cheung HC; Bo T; Duh MS; Hirji I
J Med Econ; 2022; 25(1):367-380. PubMed ID: 35240904
[TBL] [Abstract][Full Text] [Related]
15. Evolving Therapeutic Options for Chronic Graft-versus-Host Disease.
Gonzalez RM; Pidala J
Pharmacotherapy; 2020 Aug; 40(8):756-772. PubMed ID: 32441379
[TBL] [Abstract][Full Text] [Related]
16. Retrospective database analysis of healthcare resource utilization and costs in patients who develop post-transplant lymphoproliferative disease within the first year following allogeneic hematopoietic stem cell transplants.
Watson C; Xu H; Princic N; Sruti I; Barlev A
J Med Econ; 2020 Oct; 23(10):1159-1167. PubMed ID: 32643493
[TBL] [Abstract][Full Text] [Related]
17. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
18. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
[TBL] [Abstract][Full Text] [Related]
19. Subjective Oral Dryness following Hematopoietic Cell Transplantation: A Report from the Orastem Study.
Bulthuis MS; van Leeuwen SJM; Thomas RZ; van Gennip LLA; Whiteside HM; Isom S; Kline DM; Laheij AMGA; Raber-Durlacher JE; Hasséus B; Johansson JE; Hovan AJ; Brennan MT; von Bültzingslöwen I; Huysmans MDNJM; Blijlevens NMA
Transplant Cell Ther; 2024 Apr; 30(4):446.e1-446.e11. PubMed ID: 38242439
[TBL] [Abstract][Full Text] [Related]
20. Economic burden of acute steroid-refractory graft-versus-host disease in commercially insured pediatric patients.
Grabner M; Strati E; Sandman K; Forsythe A
J Manag Care Spec Pharm; 2021 May; 27(5):607-614. PubMed ID: 33908282
[No Abstract] [Full Text] [Related]
[Next] [New Search]